Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
48.03 USD -7.31% Intraday chart for Apellis Pharmaceuticals, Inc. -15.50% -19.76%
Apr. 17 Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating MT
Apr. 09 Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
GL
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
MT
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
GL
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
AQ
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
CI
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:00 AM
Transcript : Apellis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-03-2024 through Mar-06-2024
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLS Stock
  4. News Apellis Pharmaceuticals, Inc.